Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The comp... Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0624 | -31.2 | 0.2 | 0.2 | 0.2 | 0 | 0 | CS |
| 4 | -0.0624 | -31.2 | 0.2 | 0.2 | 0.2 | 0 | 0 | CS |
| 12 | -1.0424 | -88.3389830508 | 1.18 | 1.22 | 0.121 | 410957 | 0.50153028 | CS |
| 26 | -0.7753 | -84.9271552196 | 0.9129 | 3.39 | 0.121 | 1788275 | 1.2656403 | CS |
| 52 | -3.5924 | -96.3109919571 | 3.73 | 7.6699 | 0.121 | 1599522 | 2.23223928 | CS |
| 156 | -77.6624 | -99.8231362468 | 77.8 | 89.566 | 0.121 | 812946 | 6.93806709 | CS |
| 260 | -75.8624 | -99.8189473684 | 76 | 486.8 | 0.121 | 752469 | 59.00138243 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
